UK MHRA appoints Professor Jacob George as first CMSO
From today, 5 January 2026, the UK’s medicines regulator has a new science lead. The Medicines and Healthcare products Regulatory Agency (MHRA) has appointed Professor Jacob George as its first Chief Medical and Scientific Officer to guide the agency’s science strategy and its research and innovation work, the MHRA said in a press release.
A quick refresher before we go further. The MHRA is the public body that signs off every medicine and medical device used in the UK. Its core job is to make sure products work as intended and are acceptably safe, and it sits within the Department of Health and Social Care. When you hear about approvals for vaccines, asthma inhalers or insulin pumps, this is the regulator making the call.
So what will a CMSO actually do? Think of this post as the MHRA’s science compass. The CMSO sets the direction for evidence standards, oversees agency‑wide research, and helps ensure that promising ideas are assessed fairly and thoroughly. The aim is straightforward: keep patient safety central while encouraging useful innovation to move from labs to clinics with less confusion and delay.
Who is Professor George? He is Professor of Cardiovascular Medicine and Therapeutics at the University of Dundee and a consultant physician in NHS Tayside. He has worked with the Innovative Licensing and Access Pathway (ILAP), co‑chaired an NIHR capital committee, and previously advised NICE on health technologies-experience that blends frontline medicine, academia and regulation.
Ministers and the agency’s leadership frame the appointment as a way to speed access without lowering standards. Health Innovation Minister Dr Zubir Ahmed pointed to quicker, safer access to modern treatments, and MHRA Chief Executive Lawrence Tallon linked the role to faster access to medicines and devices across all four nations. In short: quicker, but still careful.
You’ll also see this tied to ILAP, a programme that brings the MHRA, the NHS and health technology bodies together early so developers get joined‑up advice. The goal is to cut the time it takes genuinely transformative medicines to reach patients by coordinating regulatory, clinical and value evidence from the start, including the ‘Innovation Passport’ step for eligible products.
What this means for you as a patient or carer is clarity and consistency. When regulators, the NHS and evidence bodies pull in the same direction, side‑effect monitoring, patient information and access decisions are easier to follow. For students and early‑career researchers, it means designing studies with real‑world use in mind: stronger trial endpoints, clear safety reporting and open communication with regulators.
Timeline check: the MHRA first announced Professor George’s appointment on 4 November 2025, with a start date of 5 January 2026. That matters because scientific leadership shapes the guidance and signals you’ll see throughout the year-from clinical trial advice to how the agency weighs patient input on new treatments.